Participants in a trial testing Lykos Therapeutics’ experimental ecstasy-based drug previously told the news outlet they felt pressured to report positive outcomes. Some trial subjects also alleged shortfalls in side-effect reporting and researchers illicitly offering MDMA, commonly known as ecstasy.
The drugmaker said it is not aware of researchers illegally distributing MDMA and that its data is reliable.
Lykos submitted a new approval application for its drug midomafetamine after finding symptom reduction among post-traumatic stress disorder patients, but the FDA rejected the therapy Aug. 5 and requested a new clinical trial.
FDA investigators have interviewed four people about the research and whether side effects went unreported, people familiar with the matter told WSJ. The investigation is ongoing.
“Lykos is committed to engaging with the FDA and addressing any questions it raises,” a company spokesperson told WSJ.
The drugmaker plans to lay off about 75% of its workforce after the FDA’s rejection of its drug application.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
